A well-known multinational pharmaceutical enterprise business restructuring, will lay off 720 people!

[industry news of pharmaceutical network] on February 6, GSK began to implement a two-year restructuring plan in its Belgian vaccine business department, which will lay off 720 employees This staffing change will involve employees in R & D, manufacturing and global support functions In addition, GSK also decided to terminate the renewal of the temporary labor contract for 215 employees GSK said the purpose of the staff adjustment is to improve the efficiency of the company and establish a "common method" for research and development between drugs and vaccines to help pharmaceutical companies decide which candidate drugs are the right choice for the company The restructuring of GSK's vaccine business will cut 720 jobs It is reported that on February 5, GSK announced its plan to split the company into two entities in the next two years: one will focus on drugs and drug development, the other will focus on consumer healthcare products GSK expects the one-time cost of the spin off to be around £ 600-700 million, while the two-year spin off plan will cost £ 2.4 billion, including £ 1.6 billion in cash Through the split, GSK aims to save £ 700m per year by 2022 and improve operational performance from 2022 In addition, GSK has begun to prepare for the large-scale division of consumer healthcare business while restructuring and downsizing the vaccine business In fact, due to the past decade, the productivity problems that have plagued large pharmaceutical companies have been basically solved In recent years, the management team of large pharmaceutical enterprises has been committed to increasing performance in various ways Therefore, the corresponding strategic adjustments and business divestitures, as well as layoffs and other situations have occurred from time to time For example, recently, MSD announced that it would spin off its women's health products, mature products and bio generic products, establish a new independent listed company, and retain its key growth point products such as tumor, vaccine, in-hospital products and animal health care In addition, on October 23 last year, Novartis also announced that it would eliminate 320 jobs in Ireland, involving 240 employees in the "active pharmaceutical ingredients (API)" factory and 80 employees in the "global services" department According to Novartis' previous response to the media, the above layoffs will also be completed in the middle of 2022, which will help streamline the organizational structure and concentrate resources on innovation and R & D And earlier in November 2018, Bayer, the German chemical and pharmaceutical group, announced in a statement that it planned to cut 12000 jobs by the end of 2021 In addition, Bayer will withdraw from its animal health business and its Coppertone sun care and Dr scholl foot care product line, boosting its core pharmaceutical and agricultural businesses In fact, in addition to business restructuring, the strong alliance among pharmaceutical enterprises is also the normal state of multinational pharmaceutical enterprises in recent years In July 2019, Pfizer and mylan announced an agreement to merge mylan with Upjohn, Pfizer's non patent brand and generic pharmaceutical division, to create a new global pharmaceutical company, with revenues expected to reach $19 billion to $20 billion in 2020 In November 2019, AstraZeneca, a biopharmaceutical enterprise, announced to enter into a long-term and multi-faceted global strategic partnership with Omron Health Care Co., Ltd and signed a memorandum of strategic cooperation In the future, AstraZeneca will jointly develop disease management solutions in the fields of respiration, cardiovascular and metabolism for patients